Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Motif Bio PLC invited to prestigious life sciences partnering conference

BIO-Europe Spring is designed to provide top level partnering opportunities for smaller life science companies
Motif Bio PLC invited to prestigious life sciences partnering conference
The conference annually attracts an international "who's who" from biotech, pharma, and finance for three days networking and meetings

Motif Bio plc (LON:MTFB) is  to present at the prestigious BIO-Europe Spring conference in Stockholm next month to help its search for a partner for its new antibiotic iclaprim.

Graham Lumsden, Motif Bio’s chief executive, will give the presentation on Tuesday, 5 April.

BIO-Europe Spring  is designed to provide top level partnering opportunities for smaller life science companies.

The conference annually attracts an international "who's who" from biotech, pharma, and finance for three days networking and meetings, Motif said.

The group recently dosed its first patient in one of two phase III clinical trials planned for iclaprim while it also appointed The Fulford Group to assist with the commercialisation of the drug.

Lumsden recently told Proactive Investors the company is looking for “one or two partners during 2016” to help commercialise iclaprim globally, and that the Fulford Group, which “specialises in finding partners for companies like Motif,” will aid the firm to do this.

PhilW.jpg
Why Invest In Motif Bio Plc? Read More Here

Register here to be notified of future MTFB Company articles
View full MTFB profile

Motif Bio Plc Timeline

Article
November 24 2016

Related Articles

cancer cells
January 24 2017
The US-based, London-listed healthcare group topped expectations with its latest results and analysts are tipping it for more success this year
brokerreport.jpg
January 25 2017
Analyst Vadim Alexandre, of the company’s broker Northland Capital, said Wednesday’s update provided “better visibility” on the trial timetable.
Blood testing
February 13 2017
Identifying cancer cells early is a key part of combatting the disease, and ANGLE's Parsortix device looks to be developing into a key ally.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use